Dexcom (DXCM) Q4 2021 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2021 earnings summary
4 Nov, 2026Executive summary
FY2021 revenue grew 27% to $2.448B as global CGM customer additions reached a record; year-end users estimated at 1.25M.
Gross margin expanded and cash resources remained strong, while operating income and net income declined YoY amid higher investment and a one-time Verily milestone charge.
Financial highlights
Revenue was $2,448.5M, up 27% YoY; gross profit rose 31% to $1,680.5M and gross margin increased to 68.6% from 66.4%.
Operating income fell 11% to $265.8M; net income fell 69% to $154.7M, reflecting higher expenses and the prior-year tax benefit from releasing a valuation allowance.
Basic EPS was $1.60 vs. $5.23; diluted EPS was $1.55 vs. $5.06.
Revenue growth was driven by higher disposable sensor volume from customer-base expansion, partly offset by channel mix and pricing; sensor and other revenue was 84% of sales vs. 81%.
Outlook and guidance
Prior-year non-GAAP gross and operating margin expectations were exceeded; 2022 priorities include G7 regulatory clearance and launch, broader access, and continued expansion of customer reach.
Significant capital spending is expected in the next year for Malaysia manufacturing build-out and Mesa capacity expansion; available liquidity is expected to cover operating and capital needs for at least 12 months.
Revenue typically runs lower in Q1 than Q4 because of U.S. insurance deductible resets and unfunded flexible spending accounts.
Latest events from Dexcom
- Revenue grew 19% as G7 clearance and expanded CGM access strengthened growth prospects.DXCM
Q4 2022 - Revenue climbed 43% as profitability arrived and G6 capacity doubled.DXCM
Q4 2019 - 31% revenue growth and 66% gross margin, with earnings lifted by a major tax benefit.DXCM
Q4 2020 - G6-led revenue topped $1B as launch investment and the Verily charge widened losses.DXCM
Q4 2018 - Q3 revenue and margins grew, lifting FY2026 guidance and supporting a new $1B buyback.DXCM
Q3 2026 - Q4 revenue grew 26% organically as FDA submissions and G7 integrations advanced.DXCM
Q4 2023 - CONNECT data, expanded coverage, and product innovation set stage for accelerated growth.DXCM
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue rose 13%, net income 39%, margins and guidance up, $600M shares repurchased.DXCM
Q2 2026 - Q3 2024 saw 2–3% revenue growth, strong international gains, and a $750M share repurchase.DXCM
Q3 2024